Phase 4 N=30 Mechanism of Action Study for Psoriasis
Psoriasis
Primary: Biologic Activity Endpoints — -3.85; -2.83; 0.05; 0.84 fold change — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=55 Mechanisms of Action of Acetaminophen
Myocardial Infarction · Arthritis
Primary: Percent Change in Serum Thromboxane B2 — 97.0; 97.4; 98.3; 96.7 Percent inhibition of baseline — p=>0.05
N/A N=274 Pathogenesis of Adverse Drug Reactions
Seizures
Primary: Drug (Valproic Acid or Carbamazepine) Metabolite Profiles in Urine — 15.2; 13.1; 1.15; 2.13 nmol per mg creatinine
N/A N=60 Mechanisms of Glucose Lowering Effect of Colesevelam HCl
Diabetes
Primary: Fasting Endogenous Glucose Production (EGP) — 0.19; 1.59 umol per kg Fat-Free Mass (FFM) per min — p=<0.1
Phase 4 N=7 Neural Mechanisms of Disulfiram Effects
Alcohol Use Disorder
Primary: Alcohol Use — 0 days
Phase 1 N=11 Prescription Medication Interactions
Opioid Use · Sedative Use
Primary: Change in Subject-Rated Outcome: Visual Analog Scale (VAS) Drug Liking — 7.40; 39.00; 40.80; 24.50 Score on a scale — p=<0.0001
Phase 4 N=1,504 Smoking Cessation Medications: Efficacy, Mechanisms and Algorithms
Nicotine Dependence
Primary: 7-day Point Prevalence of Smoking, Biochemically (Exhaled CO) Confirmed — 90; 87; 107; 84 participants with<10 ppm exhaled CO
Phase 1 N=29 Sulforaphane as an Antagonist to Human PXR-mediated Drug-drug Interactions
Adverse Drug Interactions
Primary: Midazolam Clearance (Pharmacokinetic Measure of Cytochrome P450 3A4 Activity) — 604; 552; 541; 156 ng*min/ml
N/A N=35 Downstream Molecular Signals of P2Y12 Receptors in Hyporeactive Patients Under Clopidogrel Treatment A Possible Mechanism of HOTPR(High On-Treatment Platelet Reactivity)
Stable Angina
Primary: PRU(Platelet Rreactivity Unit) 24 Hours After DAPT(Dual AntiPlatelet Therapy) Western Blot After Medication — 148; 289; 79; 132 PRU(Platelet Rreactivity Unit)
Phase 4 N=30 Effect of Methylnaltrexone on the PK/PD Profiles of Ticagrelor in Patients Treated With Morphine
Coronary Artery Disease
Primary: Platelet Reactivity Measured by VerifyNow P2Y12 — 130; 97 PRU — p=0.261
Phase 4 N=24 Pharmacokinetics Study of Dipeptidyl Peptidase 4 Inhibitor to Control Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Plasma Concentration of Active Glucagon-like Peptide 1 (GLP-1) Before and After Sitagliptin Treatment — 7.0; 6.1; 10.6; 14.1 pmol/L
N/A N=13,021 Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - PDE5
Pulmonary Arterial Hypertension
Primary: Time to Dementia Onset — 17.9; 18.8; 19.8; 19.9 Incidence rate per 1000 person year
Phase 2 N=18 Pharmacogenetics of Naltrexone for Stimulant Abuse
Substance Use Disorders · Methamphetamine Abuse
Primary: Methamphetamine Self-Administration — 8890; 7116 Clicks on a computer mouse
Phase 2 N=74 Pharmacogenetics of Disulfiram for Cocaine
Cocaine Dependence · Opioid Dependence
Primary: Urine Toxicology for Cocaine. — 84; 68; 56; 67 % cocaine + urines over 2 week blocks
Phase 4 N=77 Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI
Coronary Artery Disease · Acute Coronary Syndrome
Primary: Platelet Reactivity Measured by VerifyNow — 23; 153; 65 PRU
Phase 1 N=30 Single-dose and Steady-state Pharmacokinetics of BIA 2-093 and Its Metabolites
Epilepsy
Primary: Maximum Drug Concentration (Cmax) — 9469; 9867; 15067; 17309 ng/mL
N/A N=121 Developmental Regulation of Proteins Responsible for Transforming Drugs in the Body
Healthy
Primary: Change in CYP2D6 Drug Metabolism Phenotype With Age — -1.974; -2.083; -2.162; -2.073 unitless ratio — p=0.035
Phase 4 N=62 Effect of QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) on Cardiac Function in COPD Patients
Chronic Obstructive Pulmonary Disease, COPD
Primary: Change in Left Ventricular End-diastolic Volume (LVEDV) — 11.873; -0.954 ML — p=<0.0001
Phase 2 N=7 Pharmacotoxicology of Trichloroethylene Metabolites
Healthy
Primary: Plasma DCA (Microgram/ml) After 5 Days of Therapeutic Level Chloral Hydrate on Arm 2A. — 1.64 micrograms/ml
Phase 2 N=50 Psychopharmacology for Cocaine Dependence - Buspirone
Cocaine Dependence
Primary: Attentional Bias as Assessed by Score on the Stroop Task — -13.90333; 27.118; -9.361269; 15.35407 milliseconds
Phase 4 N=33 The Effect of a Peroxisome Proliferator-activated Receptor (PPAR) Alpha Agonist on Cytochrome P450 (CYP) Monooxygenase Activity in Humans
Hypertension
Primary: Change in Blood Pressure During High Salt Intake and Fenofibrate Treatment Compared to High Salt Intake and Placebo Treatment — 2.0; -3.4 mm Hg
Phase 4 N=107 Mechanisms for the Effect of Acetylcysteine on Renal Function After Exposure to Radiographic Contrast Material
Radiocontrast-induced Nephropathy
Primary: Changes in Renal Blood Flow — 9590.8; 5105.4; 8529.4; 5228.4 h.mL/min
Phase 2 N=12 Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis
Plaque Psoriasis
Primary: Percentage of Participants Achieving a 75% Reduction in the Psoriasis Area and Severity Index (PASI75) at Week 12 — 62.50; 33.33 percentage of participants
Phase 4 N=74 (Botox) Mechanisms of Action in Altering the Molecular Environment in Which Pain Fibers Exist
Migraine
Primary: Inflammatory Gene Expression in Chronic Migraine Patients With OnabotulinumtoxinA Injection Treatment Versus No Treatment — 44.46156; 68.74241 mRNA units — p=<0.0001
N/A N=14 Pharmacotoxicology of Trichloroethylene Metabolites
Congenital Lactic Acidosis
Primary: Hypothesize That Subject's Genotype Will Determine How DCA is Metabolized. — 1592; 232 Minutes — p=0.023
N/A N=52 The Medication Metronome Project - Study to Facilitate Follow-up Testing Resulting From Prescribed Medications to Improve Patient Safety and Care
Diabetes Mellitus, Type 2 · Hypertension · Hyperlipidemia
Primary: Primary Effectiveness Outcome - LDL — 57.9; 54.8 percentage of time spent at goal
N/A N=31 Methadone Monitoring for Insights Into Adverse Events
Pain · Opiate Addiction
Primary: Total Methadone Peak Plasma Concentration — 107.3; 315.4; 362.2 ng/mL
Phase 4 N=20 Defibrotide in the Human Endotoxemia Model --- an Exploratory Trial Investigating the Effects and the Mechanisms of Defibrotide
Healthy Volunteers · Endotoxemia
Primary: Prothrombin Fragments f1+2 — 31.1; 34.08; 27.41; 36.02 fold-change*h — p=0.408
Phase 1 N=30 Transporter Cocktail Mutual Interaction
Healthy
Primary: Area Under the Curve of Digoxin From 0 to Last Quantifiable Data Point (AUC 0-tz) — 11.549; 11.981 nanomole hour per liter (nmol·h/L)
Phase 1 N=8 Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine]
Methamphetamine Use Disorder
Primary: Reinforcing Effects of Methamphetamine Following Methylphenidate (0 mg; Placebo) Maintenance. — 0; 0; 3.33; 7.25 Trials Completed